Sistem Delcath, HEPZATO KIT
Melphalan disatujuan ku FDA salaku pangobatan ati pikeun melanoma uveal
Nov 2023: The Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System, Delcath Systems, Inc.) as a liver-directed treatment for adult patients with uveal melanoma who have unresectable h..
Cina, percobaan klinis, karsinoma hepatosél, JW Therapeutics, Shanghai
JW Therapeutics Ngumumkeun Inisiasi Studi Klinis JWATM214 di Pasén sareng Karsinoma Hépatoseluler Lanjut
SHANGHAI, CHINA, 28 Pebruari 2023 - JW Therapeutics (HKEX: 2126), perusahaan biotéhnologi mandiri sareng inovatif anu museurkeun kana ngembangkeun, manufaktur sareng komersialisasi produk immunotherapy sél, ngumumkeun…
durvalumab, karsinoma hepatosél, tremelimumab
Tremelimumab disatujuan ku FDA dina kombinasi sareng durvalumab pikeun karsinoma hépatoselular anu teu tiasa diréduksi
November 2022: The Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Efficacy was evaluat..
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Ubar disatujuan pikeun pengobatan kanker ati
Des 2021: Ubar-ubar di handap ieu disatujuan pikeun pengobatan kanker ati: Punten parios inpormasi resep sateuacan nyandak ubar. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-SM..
cangkok ati, Cangkok ati di Apollo Chennai
Bedah kanker haté sareng cangkok ku Dr. Selvakumar
July 14, 2021: Check out interview of Dr. Selvakumar Naganathan - Clinical Lead - Liver transplantation and HPB surgery, Apollo Hospitals, Chennai. Check out the video and also excerpts of the interview. https://www.youtube.com..
Atezolizumab, Bevacizumab, Obat pangénggalna
Atezolizumab plus Bevacizumab pikeun pangobatan kanker ati
Juli 13th 2021: Pangobatan novél pikeun jalma anu ngagaduhan jenis kanker ati anu disebut karsinoma hépatokellular sayogi anu katingalina langkung saé tibatan terapi standar (HCC). Administrasi Pangan sareng Narkoba (FDA) nyatujuan atezoliz ..
CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, karsinoma hepatosél, Sorafenib, USFDA
Cabozantinib disatujuan ku FDA pikeun karsinoma hépatokellular
On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. The appr..
Perawatan kanker ati dina taun 2023
Beungbeurat kanker ati Kanker ati mangrupakeun tumor ganas umum akuntansi pikeun leuwih ti satengah tina kanker ati global. Awal carcinoma hépatocellular (HCC) disumputkeun, sarta gejala awal teu atra. Kalolobaan jalma..
Imunoterapi pang anyarna dina pangobatan kanker ati
Kanker ati Kanker ati ayeuna mangrupikeun panyabab paling umum kalima tina maotna anu aya hubunganana sareng kanker di dunya. Obat pengobatan sistemik lini kahiji ayeuna utamana sorafenib, tapi biasana ngan ukur manjangkeun kasalametan sakabéh 3 bulan.
Imunoterapi sél NK dina kasus kanker ati anu maju
Kasus imunoterapi sél NK pikeun kanker ati canggih Pasién kanker maju 92 taun parantos remisi lengkep Tujuh taun ka pengker, Ibu M, anu umurna 80an, didiagnosis karsinoma hépatoselular (disababkeun ku kanker dina p..